导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.62% | 2684/4773 |
| 近一周 | -3.00% | 3537/5462 |
| 近一月 | -7.86% | 4016/5421 |
| 近一季 | -14.52% | 4167/5209 |
| 近半年 | -3.00% | 2091/4920 |
| 近一年 | 0.56% | 2538/4366 |
| 近两年 | 54.79% | 1346/2954 |
| 近三年 | 26.71% | 1197/2253 |
| 成立以来 | 45.18% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.93% 2562/4961 |
21.29% 1181/5312 |
- - |
- - |
| 2025 | 24.78% 1769/4813 |
-0.92% 2464/3635 |
-0.94% 3067/4076 |
29.81% 1204/4524 |
-2.07% 3081/4813 |
| 2024 | 11.85% 1295/3463 |
0.19% 1027/2808 |
-3.45% 1373/3014 |
19.46% 845/3129 |
-3.21% 2293/3463 |
| 2023 | -16.20% 1674/2656 |
4.30% 989/2280 |
-6.51% 1657/2385 |
-7.55% 1590/2515 |
-7.05% 2027/2655 |
| 2022 | -25.06% 1286/2207 |
-18.48% 1346/1919 |
8.66% 340/2016 |
-16.49% 1463/2113 |
1.31% 1310/2208 |
| 2021 | -1.23% 788/1822 |
-5.16% 907/1255 |
10.25% 484/1330 |
-8.02% 1096/1466 |
2.71% 533/1822 |
| 2020 | 47.50% 196/1250 |
-5.63% 431/1028 |
21.52% 232/1067 |
9.95% 602/1164 |
16.98% 143/1184 |
| 2019 | 53.21% 84/1092 |
36.81% 77/739 |
-3.06% 367/788 |
4.15% 215/850 |
10.92% 88/918 |
| 2018 | -33.46% 553/834 |
- - |
-11.06% 346/631 |
-9.80% 531/660 |
-14.39% 586/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 融通深证100指数C VS. 长安沪深300非周期A(740101) |